DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2009/0305319 A1 Baudenbacher Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2009/0305319 A1 Baudenbacher Et Al US 20090305319A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0305319 A1 Baudenbacher et al. (43) Pub. Date: Dec. 10, 2009 (54) APPARATUS AND METHODS FOR (21) Appl. No.: 10/213,049 MONITORING THE STATUS OF A METABOLICALLY ACTIVE CELL (22) Filed: Aug. 6, 2002 (76) Inventors: Franz J. Baudenbacher, Franklin, Related U.S. Application Data TN (US); John P. Wikswo, Brentwood, TN (US); R. Robert (60) Provisional application No. 60/310,652, filed on Aug. Balcarcel, Nashville, TN (US); 6, 2001. David Cliffel, Nashville, TN (US); Sven Eklund, Antioch, TN (US); Publication Classification Jonathan Mark Gilligan, (51) Int. Cl. Nashville, TN (US); Owen CI2O 1/02 (2006.01) McGuinness, Brentwood, TN (US); CI2M 3/00 (2006.01) Todd Monroe, Baton Rouge, LA (US); Ales Prokop, Nashville, TN (52) U.S. Cl. ........................................ 435/29: 435/287.1 (US); Mark Andrew Stremler, Franklin, TN (US); Andreas (57) ABSTRACT Augustinus Werdich, Nashville, TN (US) An apparatus and methods for monitoring the status of a cell that consumes oxygen. In one embodiment of the present Correspondence Address: invention, the method includes the steps of confining the cell MORRIS MANNING MARTIN LLP in a sensing Volume, measuring dynamically intracellular or 3343 PEACHTREE ROAD, NE, 1600 ATLANTA extracellular signaling of the cell, and determining the status FINANCIAL CENTER of the cell from the measured intracellular or extracellular ATLANTA, GA 30326 (US) signaling of the cell. Patent Application Publication Dec. 10, 2009 Sheet 1 of 41 US 2009/0305319 A1 108 Biological Ya aga stimulator r c X Generator 109 i 112 1 10 2. System i models 111 114 113 116 Fig. 1 Patent Application Publication Dec. 10, 2009 Sheet 2 of 41 US 2009/0305319 A1 /7 I (X) 20 273 283 L 271 28 1 Fig. 2B Patent Application Publication Dec. 10, 2009 Sheet 3 of 41 US 2009/0305319 A1 Fig. 3B 309 311 -211 X---------X% - H 2 %t YZZ 31 O S&2% O X) % 4%1. C 2> 306 %22 % % XXX). 22 ZZ2 2 Patent Application Publication Dec. 10, 2009 Sheet 4 of 41 US 2009/0305319 A1 Fig. 4B Patent Application Publication Dec. 10, 2009 Sheet 5 of 41 US 2009/0305319 A1 400 N OOOOO kif | S21 Patent Application Publication Dec. 10, 2009 Sheet 6 of 41 US 2009/0305319 A1 500 590 58, 583 551.41 524 593 521b 592 595 52 a. 573 521C 580 X F-776 X 47-a- ENN R - 5A.as S 9 booe $63 505 509b 509C 553 - 512 513 559 508 52 506 508 Fig. 5A 503 515 501 565 Patent Application Publication Dec. 10, 2009 Sheet 7 of 41 US 2009/0305319 A1 515 1 7 G O)NS43 T I It 592 575 57.1 573 Fig. 5C Patent Application Publication Dec. 10, 2009 Sheet 8 of 41 US 2009/0305319 A1 610 615 602 66 613 659 611 607 606 608 605 Fig.6A 0. 617 603 '' 602 611 607 sos 608 605 Fig. 6B Patent Application Publication Dec. 10, 2009 Sheet 9 of 41 US 2009/0305319 A1 64 Fig. 6C 601 612 6 13 SO 3 Fig. 6D Patent Application Publication Dec. 10, 2009 Sheet 10 of 41 US 2009/0305319 A1 Fig. 7A 708 701 702 709 721 703 707 Fig. 7B Patent Application Publication Dec. 10, 2009 Sheet 11 of 41 US 2009/0305319 A1 Patent Application Publication Dec. 10, 2009 Sheet 12 of 41 US 2009/0305319 A1 BioPhysical Microcontroller Design Environment 802 ag 804 805 Bio(Metabolic) Cell Diagnosis Models Physical(Sensoreffectol) Models ControlModels Strategy Models 813 814 Application-Specific 809 807 Bio- Microcontroller Fig. 8 Patent Application Publication Dec. 10, 2009 Sheet 13 of 41 US 2009/0305319 A1 Agents RiCin WX Unknown PicoCalorimeter Te Levi + 5%, SNR 20 Levi - 10%, SNR 3 901 Ep Levi 10%, SNR 2 Levi 10%, SNR 2 Nanobiofreactor R e X Stopes 10 SNR 20 Slope-20 SNR 5 Slope C 0 SNR 2 Lev +25%, SNR 4 Lev +25%, SNR 4 Lev + 25%, SNR 4 ev + 10 SNR 3 Lev - 10 SNR 3 ev + 10 SNR 3 AutoPatchClamp ley + 15 SNR 3 Lev + 5 SNR 3 lev - 15 SNR 3 ev + 8 SNR 2 Lew 4- 8 SNR 2 ev + 8 SNR2 ?t + SNR2 it nt - SNR2 & Optical Tags int- SNR 4 it rt SNR 2 D Pos SNR 7 Pos P OS SNR 2 R t Neg SNR 2 Neg SNR 2 Ne SNR2 Clev SR 4 SNR > Lee SNR 4 Ley. SNR 4 ev, SNR 4 9,R EEEv. SNRs V Ecy. SNRs liee. SNRG O evsnra NewsNR4Test > evisit New SNR 2 le. SNR > TestNR6 Nev. SNRs Lev. SR 6 New SNR4 ev. SNR 4 -- - - TO OC CYD. O A. Dow. At Co 7. 9 O 5 Fig. 9 Patent Application Publication Dec. 10, 2009 Sheet 14 of 41 US 2009/0305319 A1 296 996 313996V6 Patent Application Publication Dec. 10, 2009 Sheet 15 of 41 US 2009/0305319 A1 1 OO1 1 OO2 1003 1004 5 2, 2,5 3.0 3,5 4.0 Time in hours Fig. 10 Patent Application Publication Dec. 10, 2009 Sheet 16 of 41 US 2009/0305319 A1 Fig. 1 1A 1166 1162 1151 SS 1129 EŠirl 6. Fig. 11B Fig. 11C 1128 1151 Patent Application Publication Dec. 10, 2009 Sheet 17 of 41 US 2009/0305319 A1 1200 B t 1204 12O6 1215 A 1209 /N 1 1202 12O6 12O7 Fig. 12B Patent Application Publication Dec. 10, 2009 Sheet 18 of 41 US 2009/0305319 A1 1320 1311 Fig. 13A 1309 131 O Fig. 13B 1308 Fig. 13C Patent Application Publication Dec. 10, 2009 Sheet 19 of 41 US 2009/0305319 A1 1424 Patent Application Publication Dec. 10, 2009 Sheet 20 of 41 US 2009/0305319 A1 1503 Fig. 15 Patent Application Publication Dec. 10, 2009 Sheet 21 of 41 US 2009/0305319 A1 16O2 1612 1606 1605 1611 N. Oxidative -1 Phosphorylation Fig. 16 Patent Application Publication Dec. 10, 2009 Sheet 22 of 41 US 2009/0305319 A1 1704 1705 O 60 Time (min) Fig. 17A infuse Cyanide 1701 1 7 O 5 Time (min) Fig. 17B Patent Application Publication Dec. 10, 2009 Sheet 23 of 41 US 2009/0305319 A1 Macrophage - Infuse - endotoxin Time (min) Fig. 18A Hepatocyte 1811 - Infuse -: endotoxin Time (min) Fig. 18B Patent Application Publication Dec. 10, 2009 Sheet 24 of 41 US 2009/0305319 A1 No phenobarbital preexposure 0 Time (min) 60 Fig.19A Phenobarbital preexposure :- infuse VX 191 0 Time (min) 60 Fig.19B Patent Application Publication Dec. 10, 2009 Sheet 25 of 41 US 2009/0305319 A1 2OO1 1 mM 1 OnM 2002 Glucose Glucose G.) 9 9 CO O 5 C s of D CS2 C CD O. d) .9) C E. of 9. O A) 2 CD 0 Time (min) 60 Fig. 20 Patent Application Publication Dec. 10, 2009 Sheet 26 of 41 US 2009/0305319 A1 2101 21 O2 ACtion potential Time Fig. 21 Patent Application Publication Dec. 10, 2009 Sheet 27 of 41 US 2009/0305319 A1 2200 2203 2204 22O1 POtOCO Definition Zoom on Specific- - - Protocol Step St 5E Feature Extraction Lib Bif Broad 2251 Aria O is: Data Point Lib ) E) E-2205 225 GOs Ye 2253 Viral S5 EEEEEE FF-Sun is br- 259 SE OOOO b: Dif stop- 2206 2257 Neuro 4 -4, 2ASS gs oscin funct OO) 4 0 OOOOOO gS. \ CCHist PotocoSelect PotocolSelect PotocoSelect Data Path 1 Path 2 Path 3 22O2 V w 2208 2209 22O7 Fig. 22 Patent Application Publication Dec. 10, 2009 Sheet 28 of 41 US 2009/0305319 A1 230 2351 2301 p 23O3 J 2304 / Feature Space of-7 -- - - - - O2C PGA &: six-is: GK) Classify r - - - - 2305 Confidence Factor: 20% r Metabolic Model-F3) Fit to Feature Space 2nd Order PCA Classify 2313 2314 Patent Application Publication Dec. 10, 2009 Sheet 29 of 41 US 2009/0305319 A1 2400 2405 2404 Celle Mac?ophage Liver Broad Sensors: Heat Oxygen. Free Radca? NADPH.GlukconegenSIS Spectrum Activity feat Extraction:Slope and AU 24O6 24O1 Expected. Both NADPHOvergent Response ity REF: ABLE xxx 24O7 Computed Robustness: 19% 24.08 Gram-Negative Celtine: Macophage-cD4) Bacteria ASSa Sensors: Heat. Oxygen. Fee RadcasADPH 2402 feat Extraction:Siope and AJC Expected: DSCIn on Activation Robustness Factor:40% Path/No Path Celine: intestical Celine Bacteria ASSa Sensots: Heat. Oxygen. Free Radical NADPH 2403 Feat Extraction:Slope and AUC Expected: Discriminor Mel Leyes Robustness Factor:80, Patent Application Publication Dec. 10, 2009 Sheet 30 of 41 US 2009/0305319 A1 2500 2573 Patent Application Publication Dec. 10, 2009 Sheet 31 of 41 US 2009/0305319 A1 500 or -- pt adding acid 1 v mV pass 1 -O-ph adding base2 v mV pass2 -o- pH adding acid3 v nV pass3 -o- pH adding base4 v mV passa 450 - i 8s 400 - IRO, pH g : Electrode 350 - 3. 300 - s s Eo 250 200 - 50 - Trr ninth wr - - - - - - - - - - - - - - - - - - 4 5 6 7 8 9 pH Patent Application Publication Dec. 10, 2009 Sheet 32 of 41 US 2009/0305319 A1 2702 se O - see - - - - - - -- N N - Y - N. N. v Fig.27A 2708 Patent Application Publication Dec. 10, 2009 Sheet 33 of 41 US 2009/0305319 A1 28O1 a. 2808 28 O2 N . 28 05 B -3% s B --isS 2S1s16-- 28 O4 > 2809 - Fig. 28B Patent Application Publication Dec. 10, 2009 Sheet 34 of 41 US 2009/0305319 A1 2808 2804 2801 Patent Application Publication Dec. 10, 2009 Sheet 35 of 41 US 2009/0305319 A1 Fig. 29B Patent Application Publication Dec. 10, 2009 Sheet 36 of 41 US 2009/0305319 A1 2912 2905 29O.
Load more

Recommended publications
  • TETANUS in ANIMALS — SUMMARY of KNOWLEDGE Malinovská, Z
    DOI: 10.2478/fv-2020-0027 FOLIA VETERINARIA, 64, 3: 54—60, 2020 TETANUS IN ANIMALS — SUMMARY OF KNOWLEDGE Malinovská, Z., Čonková, E., Váczi, P. Department of Pharmacology and Toxicology University of Veterinary Medicine and Pharmacy in Košice, Komenského 73, 041 81 Košice Slovakia [email protected] ABSTRACT the effects of the neurotoxin. The treatment is difficult with an unclear prognosis. Tetanus is a neurologic non-transmissible disease (often fatal) of humans and other animals with a world- Key words: animal; Clostridium tetani; toxin; spasm; wide occurrence. Clostridium tetani is the spore produc- treatment ing bacillus which causes the bacterial disease. In deep penetrating wounds the spores germinate and produce a toxin called tetanospasmin. The main characteristic sign INTRODUCTION of tetanus is a spastic paralysis. A diagnosis is usually based on the clinical signs because the detection in the Of the clostridial neurotoxins, botulinum neurotoxin wound and the cultivation of C. tetani is very difficult. and tetanus neurotoxin are the most potent toxins [15]. Between animal species there is considerable variabili- Their extraordinary toxicity is caused by neurospecificity ty in the susceptibility to the bacillus. The most sensi- and metalloprotease activity, which results in the paralysis. tive animal species to the neurotoxin are horses. Sheep Tetanus is potentially a fatal disease and in some countries and cattle are less sensitive and tetanus in these animal it is still very active. Tetanus is a traumatic clostridiosis, species are less common. Tetanus in cats and dogs are an infection in humans and other animals with worldwide rare and dogs are less sensitive than cats.
    [Show full text]
  • Immune Effector Mechanisms and Designer Vaccines Stewart Sell Wadsworth Center, New York State Department of Health, Empire State Plaza, Albany, NY, USA
    EXPERT REVIEW OF VACCINES https://doi.org/10.1080/14760584.2019.1674144 REVIEW How vaccines work: immune effector mechanisms and designer vaccines Stewart Sell Wadsworth Center, New York State Department of Health, Empire State Plaza, Albany, NY, USA ABSTRACT ARTICLE HISTORY Introduction: Three major advances have led to increase in length and quality of human life: Received 6 June 2019 increased food production, improved sanitation and induction of specific adaptive immune Accepted 25 September 2019 responses to infectious agents (vaccination). Which has had the most impact is subject to debate. KEYWORDS The number and variety of infections agents and the mechanisms that they have evolved to allow Vaccines; immune effector them to colonize humans remained mysterious and confusing until the last 50 years. Since then mechanisms; toxin science has developed complex and largely successful ways to immunize against many of these neutralization; receptor infections. blockade; anaphylactic Areas covered: Six specific immune defense mechanisms have been identified. neutralization, cytolytic, reactions; antibody- immune complex, anaphylactic, T-cytotoxicity, and delayed hypersensitivity. The role of each of these mediated cytolysis; immune immune effector mechanisms in immune responses induced by vaccination against specific infectious complex reactions; T-cell- mediated cytotoxicity; agents is the subject of this review. delayed hypersensitivity Expertopinion: In the past development of specific vaccines for infections agents was largely by trial and error. With an understanding of the natural history of an infection and the effective immune response to it, one can select the method of vaccination that will elicit the appropriate immune effector mechanisms (designer vaccines). These may act to prevent infection (prevention) or eliminate an established on ongoing infection (therapeutic).
    [Show full text]
  • Response of Cellular Innate Immunity to Cnidarian Pore-Forming Toxins
    Review Response of Cellular Innate Immunity to Cnidarian Pore-Forming Toxins Wei Yuen Yap 1 and Jung Shan Hwang 2,* 1 Department of Biological Sciences, School of Science and Technology, Sunway University, No. 5 Jalan Universiti, Bandar Sunway, Selangor Darul Ehsan 47500, Malaysia; [email protected] 2 Department of Medical Sciences, School of Healthcare and Medical Sciences, Sunway University, No. 5 Jalan Universiti, Bandar Sunway, Selangor Darul Ehsan 47500, Malaysia * Correspondence: [email protected]; Tel.: +603-7491-8622 (ext. 7414) Academic Editor: Jean-Marc Sabatier Received: 23 August 2018; Accepted: 28 September 2018; Published: 4 October 2018 Abstract: A group of stable, water-soluble and membrane-bound proteins constitute the pore forming toxins (PFTs) in cnidarians. They interact with membranes to physically alter the membrane structure and permeability, resulting in the formation of pores. These lesions on the plasma membrane causes an imbalance of cellular ionic gradients, resulting in swelling of the cell and eventually its rupture. Of all cnidarian PFTs, actinoporins are by far the best studied subgroup with established knowledge of their molecular structure and their mode of pore-forming action. However, the current view of necrotic action by actinoporins may not be the only mechanism that induces cell death since there is increasing evidence showing that pore-forming toxins can induce either necrosis or apoptosis in a cell-type, receptor and dose-dependent manner. In this review, we focus on the response of the cellular immune system to the cnidarian pore-forming toxins and the signaling pathways that might be involved in these cellular responses.
    [Show full text]
  • Question of the Day Archives: Monday, December 5, 2016 Question: Calcium Oxalate Is a Widespread Toxin Found in Many Species of Plants
    Question Of the Day Archives: Monday, December 5, 2016 Question: Calcium oxalate is a widespread toxin found in many species of plants. What is the needle shaped crystal containing calcium oxalate called and what is the compilation of these structures known as? Answer: The needle shaped plant-based crystals containing calcium oxalate are known as raphides. A compilation of raphides forms the structure known as an idioblast. (Lim CS et al. Atlas of select poisonous plants and mushrooms. 2016 Disease-a-Month 62(3):37-66) Friday, December 2, 2016 Question: Which oral chelating agent has been reported to cause transient increases in plasma ALT activity in some patients as well as rare instances of mucocutaneous skin reactions? Answer: Orally administered dimercaptosuccinic acid (DMSA) has been reported to cause transient increases in ALT activity as well as rare instances of mucocutaneous skin reactions. (Bradberry S et al. Use of oral dimercaptosuccinic acid (succimer) in adult patients with inorganic lead poisoning. 2009 Q J Med 102:721-732) Thursday, December 1, 2016 Question: What is Clioquinol and why was it withdrawn from the market during the 1970s? Answer: According to the cited reference, “Between the 1950s and 1970s Clioquinol was used to treat and prevent intestinal parasitic disease [intestinal amebiasis].” “In the early 1970s Clioquinol was withdrawn from the market as an oral agent due to an association with sub-acute myelo-optic neuropathy (SMON) in Japanese patients. SMON is a syndrome that involves sensory and motor disturbances in the lower limbs as well as visual changes that are due to symmetrical demyelination of the lateral and posterior funiculi of the spinal cord, optic nerve, and peripheral nerves.
    [Show full text]
  • Acute Specific Surgical Infection. Gas Gangrene. Anthrax. Diphtheria of Wounds
    Acute specific surgical infection. Tetanus. Gas gangrene. Anthrax. Diphtheria of wounds. Lecture for general surgery 2021 Chornaya I.A. Tetanus • Tetanus is an infectious disease • caused by contamination of wounds from the bacteria Clostridium tetani (an obligate anaerobic gram-positive bacillus,), or the spores they produce that live in the soil, and animal feces. • Picture of Clostridium tetani, with spore formation (oval forms at end of rods) Clostridium tetani Tetanus bacteria • Tetanus is caused by a bacterium belonging to the Clostridium genus, which thrives in the absence of oxygen. • It is found almost everywhere in the environment, most often in soil, dust, manure, and in the digestive tract of humans and animals. • The bacteria form spores, which are hard to kill and highly resistant to heat and many antiseptics. • Puncture wounds are the best entrance for the bacteria into your body Other tetanus-prone injuries include the following • frostbite, • surgery, • crush wound, • abscesses, • childbirth, • IV drug users (site of needle injection). • Wounds with devitalized (dead) tissue (for example, burns or crush injuries) or foreign bodies (debris in them) are most at risk of developing tetanus. • Tetanus may develop in people who are not immunized against it or in people who have failed to maintain adequate immunity with active booster doses of vaccine. Pathophysiology of Tetanus: • When a person gets injured, the wound or the cut becomes an environment that lacks oxygen. If the spores manage to find their way into the wound or the cut, they are able to germinate. After the spores of the bacterium germinate, they release a exotoxin, which is what causes all the ill- effects of the disease.
    [Show full text]
  • Regulation of Toxin Synthesis in Clostridium Botulinum and Clostridium Tetani Chloé Connan, Cécile Denève, Christelle Mazuet, Michel Popoff
    Regulation of toxin synthesis in Clostridium botulinum and Clostridium tetani Chloé Connan, Cécile Denève, Christelle Mazuet, Michel Popoff To cite this version: Chloé Connan, Cécile Denève, Christelle Mazuet, Michel Popoff. Regulation of toxin synthesis in Clostridium botulinum and Clostridium tetani. Toxicon, Elsevier, 2013, 75 (3), pp.90 - 100. 10.1016/j.toxicon.2013.06.001. pasteur-01792396 HAL Id: pasteur-01792396 https://hal-pasteur.archives-ouvertes.fr/pasteur-01792396 Submitted on 1 Aug 2018 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution - NonCommercial - ShareAlike| 4.0 International License 1 REGULATION OF TOXIN SYNTHESIS IN CLOSTRIDIUM BOTULINUM AND CLOSTRIDIUM TETANI Chloé CONNAN, Cécile DENÈVE, Christelle MAZUET, Michel R. POPOFF* Institut Pasteur, Unité des Bactéries Anaérobies et Toxines, Paris, France Key words: Clostridium botulinum, Clsotridfium tetani, botulinum neurotoxin, tetanus toxin, regulation Corresponding author Institut Pasteur, Unité des Bactéries Anaérobies et Toxines, 25 rue du Dr Roux, 75724 Paris cedex15, France [email protected] 2 ABSTRACT Botulinum and tetanus neurotoxins are structurally and functionally related proteins that are potent inhibitors of neuroexocytosis. Botulinum neurotoxin (BoNT) associates with non-toxic proteins (ANTPs) to form complexes of various sizes, whereas tetanus toxin (TeNT) does not form any complex.
    [Show full text]
  • Liposomes Prevent in Vitro Hemolysis Induced by Streptolysin O and Lysenin
    membranes Article Liposomes Prevent In Vitro Hemolysis Induced by Streptolysin O and Lysenin Marcelo Ayllon 1,2, Gamid Abatchev 1,2, Andrew Bogard 1,2, Rosey Whiting 1,2, Sarah E. Hobdey 3 and Daniel Fologea 1,2,* 1 Biomolecular Sciences Graduate Program, Boise State University, Boise, ID 83725, USA; [email protected] (M.A.); [email protected] (G.A.); [email protected] (A.B.); [email protected] (R.W.) 2 Department of Physics, Boise State University, Boise, ID 83725, USA 3 Idaho Veterans Research and Education Foundation and the Infectious Diseases Section, Veteran Affairs Medical Center, Boise, ID 83702, USA; [email protected] * Correspondence: [email protected] Abstract: The need for alternatives to antibiotics in the fight against infectious diseases has inspired scientists to focus on antivirulence factors instead of the microorganisms themselves. In this respect, prior work indicates that tiny, enclosed bilayer lipid membranes (liposomes) have the potential to compete with cellular targets for toxin binding, hence preventing their biological attack and aiding with their clearance. The effectiveness of liposomes as decoy targets depends on their availability in the host and how rapidly they are cleared from the circulation. Although liposome PEGylation may improve their circulation time, little is known about how such a modification influences their interactions with antivirulence factors. To fill this gap in knowledge, we investigated regular and long-circulating liposomes for their ability to prevent in vitro red blood cell hemolysis induced by two potent lytic toxins, lysenin and streptolysin O. Our explorations indicate that both regular Citation: Ayllon, M.; Abatchev, G.; Bogard, A.; Whiting, R.; Hobdey, S.E.; and long-circulating liposomes are capable of similarly preventing lysis induced by streptolysin O.
    [Show full text]
  • Host-Pathogen Interactions in Pseudmonas Aeruginosa
    HOST-PATHOGEN INTERACTIONS IN PSEUDMONAS AERUGINOSA INFECTION By CHAIRUT CHARLES VAREECHON Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Department of Pathology CASE WESTERN RESERVE UNIVERSITY August 2017 Case Western Reserve University School of Graduate Studies We hereby approve the thesis/dissertation of Chairut Charles Vareechon Candidate for the degree of Doctor of Philosophy in Pathology Committee Chair: Man-Sun Sy Committee Members: Clive Hamlin Derek Abbott Arne Rietsch Eric Pearlman Date of Defense: May 15th, 2017 We also certify that written permission has been obtained for any proprietary material contained therein 2 Table of Contents List of Tables………………………………………………………………………….. 6 List of Figures......................................................................................................7 Acknowledgements………………………………………………………………….10 List of Abbreviations….….….….….….….….….….….….….….….……….….…11 Abstract….….….….….….….….….….….….….….….….….…....….….….……...14 Chapter 1: Introduction Pseudomonas aeruginosa and Disease………….………...........….….….18 Pseudomonas aeruginosa Type III Secretion System and Virulence...…19 Targeted cells of the P. aeruginosa T3SS...….….….….….….….….….…19 T3SS the molecular syringe…………………………….……….….…..…...20 The apparatus………………………………………...….………..…..21 The translocon…………………………………………………………22 The secreted effectors……………………………….……………….23 ExoS……………………………….…………………………….24 ExoT……………………….…………………………………….26 ExoU……………….…………………………………………….27 ExoY……….…………………………………………………….28
    [Show full text]
  • Studies on the Oxidation and Reduction of Immunological Substances
    STUDIES ON THE OXIDATION AND REDUCTION OF IMMUNOLOGICAL SUBSTANCES. VII. 'I'H~. DIFFERENTIATION OF TETANOL¥SIN AND TETANOSPASMIN. BY WILLIAM L. FLEMII~G. (From the Department of Bacteriology and Immunology of Vanderbilt University Medical School, Nashzglle.) (Received for publication, May 6, 1927.) INTRODUCTION. It is well known that the tetanus bacillus produces both a hemo- toxin and a true, killing toxin (" tetanolysin" and "tetanospasmin"). Historically, the existence of the true toxin was proved (1) about 10 years before recognition of the hemotoxin by Ehrlich in 1898 (2, 3). The properties of tetanospasmin are described in detail in the larger handbooks of immunology, and the literature on the properties of tetanolysin has been reviewed in a previous paper in this series (4). Both of these products of the tetanus bacillus belong to the group of antitoxinogens and possess two fundamental properties in common: (1) they are primarily toxic substances which possess an affinity for particular cells (tetanolysin for erythrocytes and tetanospasmin for nerve cells, especially those of the gray matter of the brain); (2) they are antigenic, invoking the production of a specific neutralizing antibody (antihemotoxin and antitoxin) when systematically injected into an appropriate animal. Tetanolysin and tetanospasmin have been used as representative "antitoxinogens" in classical experiments, the results of which have been used in the establishment of many of the fundamental principles of immunology. The theoretical importance of these principles, as well as the practical importance of tetanus itself, makes it desirable to obtain a definite differentiation of these two antigenic products of the tetanus bacillus. Although it is generally recognized that hhey are 279 280 OXIDATION AND REDUCTION.
    [Show full text]
  • Toxins and Signalling Evelyne Benoit, Françoise Goudey-Perriere, P
    Toxins and Signalling Evelyne Benoit, Françoise Goudey-Perriere, P. Marchot, Denis Servent To cite this version: Evelyne Benoit, Françoise Goudey-Perriere, P. Marchot, Denis Servent. Toxins and Signalling. SFET Publications, Châtenay-Malabry, France, pp.204, 2009. hal-00738643 HAL Id: hal-00738643 https://hal.archives-ouvertes.fr/hal-00738643 Submitted on 21 May 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Collection Rencontres en Toxinologie © E. JOVER et al. TTooxxiinneess eett SSiiggnnaalliissaattiioonn -- TTooxxiinnss aanndd SSiiggnnaalllliinngg © B.J. LAVENTIE et al. Comité d’édition – Editorial committee : Evelyne BENOIT, Françoise GOUDEY-PERRIERE, Pascale MARCHOT, Denis SERVENT Société Française pour l'Etude des Toxines French Society of Toxinology Illustrations de couverture – Cover pictures : En haut – Top : Les effets intracellulaires multiples des toxines botuliques et de la toxine tétanique - The multiple intracellular effects of the BoNTs and TeNT. (Copyright Emmanuel JOVER, Fréderic DOUSSAU, Etienne LONCHAMP, Laetitia WIOLAND, Jean-Luc DUPONT, Jordi MOLGÓ, Michel POPOFF, Bernard POULAIN) En bas - Bottom : Structure tridimensionnelle de l’alpha-toxine staphylocoque - Tridimensional structure of staphylococcal alpha-toxin. (Copyright Benoit-Joseph LAVENTIE, Daniel KELLER, Emmanuel JOVER, Gilles PREVOST) Collection Rencontres en Toxinologie La collection « Rencontres en Toxinologie » est publiée à l’occasion des Colloques annuels « Rencontres en Toxinologie » organisés par la Société Française pour l’Etude des Toxines (SFET).
    [Show full text]
  • Utilización De Modelos De Calidad En Redes De Distribución De Agua Potable Para Evaluar El Riesgo Por Introducción De Sustancias Tóxicas
    UTILIZACIÓN DE MODELOS DE CALIDAD EN REDES DE DISTRIBUCIÓN DE AGUA POTABLE PARA EVALUAR EL RIESGO POR INTRODUCCIÓN DE SUSTANCIAS TÓXICAS Julián Alberto Gallego Urrea Asesor: Juan Guillermo Saldarriaga Valderrama Trabajo presentado para obtener el título de Magíster en Ingeniería Civil. UNIVERSIDAD DE LOS ANDES FACULTAD DE INGENIERIA Departamento de Ingeniería Civil y Ambiental Bogotá D.C., Agosto de 2003 Utilización de los modelos de calidad en redes de distribución de agua MIC-2003-II-43 potable para evaluar el riesgo por introducción de sustancias tóxicas. Tabla de contenido 1. Introducción.................................................................................................................... 1 2. Objetivos......................................................................................................................... 3 2.1. Objetivo General..................................................................................................... 3 2.2. Objetivos específicos.............................................................................................. 3 3. Marco teórico.................................................................................................................. 4 3.1. Conceptos de toxicidad y evaluación de riesgos .................................................... 5 3.1.1. Dosificación efectiva ...................................................................................... 5 3.1.2. Ingestión diaria aceptable ..............................................................................
    [Show full text]
  • Environmental Protection Agency § 725.422
    Environmental Protection Agency § 725.422 below in paragraphs (d)(2) through Sequence Source Toxin Name (d)(7) of this section, these comparable Bacillus anthracis Edema factor (Factors I II); toxin sequences, regardless of the orga- Lethal factor (Factors II III) nism from which they are derived, Bacillus cereus Enterotoxin (diarrheagenic must not be included in the introduced toxin, mouse lethal factor) genetic material. Bordetella pertussis Adenylate cyclase (Heat-la- (2) Sequences for protein synthesis in- bile factor); Pertussigen (pertussis toxin, islet acti- hibitor. vating factor, histamine sensitizing factor, Sequence Source Toxin Name lymphocytosis promoting factor) Corynebacterium diphtheriae Diphtheria toxin Clostridium botulinum C2 toxin & C. ulcerans Clostridium difficile Enterotoxin (toxin A) Pseudomonas aeruginosa Exotoxin A Clostridium perfringens Beta-toxin; Delta-toxin Shigella dysenteriae Shigella toxin (Shiga toxin, Shigella dysenteriae type I Escherichia coli & other Heat-labile enterotoxins (LT); toxin, Vero cell toxin) Enterobacteriaceae spp. Heat-stable enterotoxins Abrus precatorius, seeds Abrin (STa, ST1 subtypes ST1a Ricinus communis, seeds Ricin ST1b; also STb, STII) Legionella pneumophila Cytolysin (3) Sequences for neurotoxins. Vibrio cholerae & Vibrio Cholera toxin (choleragen) mimicus Sequence Source Toxin Name (6) Sequences that affect membrane Clostridium botulinum Neurotoxins A, B, C1, D, E, integrity. F, G (Botulinum toxins, botulinal toxins) Sequence Source Toxin Name Clostridium tetani Tetanus toxin
    [Show full text]